GelMEDIX is a Harvard Hospital and UCLA founded, seed-stage cell therapy company focused on enabling the next generation of vision restoring regenerative medicines. Current approaches to retinal cell replacement therapy for geographic atrophy have shown promising vision restoration potential in early clinical studies, but suffer from procedure induced adverse events (i.e., cell reflux, retinal hemorrhage) that limit their utility. GelMEDIX's proprietary, in situ forming hydrogel technology provides an injectable scaffold that protects cells and provides a framework for tissue regeneration. GelMEDIX has demonstrated compelling pre-clinical evidence of overcoming the delivery challenges with the potential to regenerate the retina with a reproducible 5.5-8x improvement in viable cell dose delivery compared to standard cell suspensions. GelMEDIX has raised $10M in seed financing and is raising $50M Series A financing to bring the lead RPE program through clinical proof-of-concept.